login cart
Home Shop Webstore Rewards Club About CBD Ordering Info Wholesale Contact Us

Get the facts about CBD:
There's a lot of hype surrounding cannabidiol benefits.
Because cannabidiol is not regulated by the United States Food and Drug Administration, manufacturers and retailers cannot legitimately make claims about the products they provide. Despite the prohibition of claims, some unscrupulous people in the industry do it anyway to convince consumers to use their products. We've designed this resource, so you can look into it yourself and decide if cannabidiol is right for you. As always, consult your physician for their perspective and so they can monitor your results. If you are a physician interested in learning more about Alpha Neurogenics cannabidiol products, contact us using our web form. We are happy to accomodate your inquiry.
US Gov't Patent
The United States Government had previously patented cannabidiol.
Cannabinoids have been found to have antioxidant properties, which makes them useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.
This discovery was made possible because of the recognition of a previously unanticipated antioxidant property of the cannabinoids in general (and cannabidiol in particular) that functions completely independently of antagonism at the NMDA, AMPA and kainate receptors. The present invention includes methods of preventing or treating diseases caused by oxidative stress, such as neuronal hypoxia, by administering a prophylactic or therapeutically effective amount of cannabinoids to a subject who has a disease caused by oxidative stress.
The US Government's patent is scheduled to expire on April 21, 2019.
Learn more about the US Government patent here.
Alzheimers research
Research shows cannabidiol may slow Alzheimer's Disease
The initial findings of a study at the Hebrew University of Jerusalem show that a non-psychoactive component of cannabis, marijuana, may hold out hope for slowing down the progression of Alzheimer’s disease. The research, still at an early stage, indicates that memory loss, the first and primary symptom of Alzheimer’s disease, can be slowed down significantly in mice by cannabidiol.
The findings were presented at the Cannabis Medicines Symposium in London, hosted by the Royal Pharmaceutical Society of Great Britain (RPSGB) and said that human trials will hopefully follow in the near future.
Dr. Clive Ballard, director of research for the UK Alzheimer’s Society, called for further research into the use of cannabis as a treatment option, saying, "We need robust clinical trials into the potential benefits of non-psychoactive components of cannabis. It is important for people to note that these treatments are not the same as recreational cannabis use, which can be potentially harmful."
Read the Israel National News article here.
Cancer Prevention
The therapeutic implications of the endocannabinoid system and cancer
The endocannabinoid system is implicated in a variety of physiological and pathological conditions: inflammation, immunomodulation, analgesia, cancer and others. We review the relationship between the endocannabinoid system and anti-tumor actions such as inhibition of cell proliferation and migration, induction of apoptosis, reduction of tumour growth of the cannabinoids in different types of cancer. This review focuses on examination on how activation of the endocannabinoid system impacts breast, prostate and bone cancers in both in vitro and in vivo systems.
Cancer is marked by uncontrolled cell division and cell death emerging from cumulative damage of important regulatory genes. Multiple genes likely need to be damaged in order for a cancer to grow and develop the ability to spread (i.e. metastasize). Cancers may be hereditary and/or caused by external (tobacco, chemicals, radiation, infectious organisms and others) and/or internal (inherited mutations, hormones, mutations from metabolism and others) factors. This review will focus on uncovering connections between the endocannabinoid system and breast, prostate and bone cancers with an emphasis on understanding how these connections could be exploited for their therapeutic anti-cancer potential.
Read the British Pharmacological Society article here.
NIH research
Emerging pharmacotherapy targets the endocannabinoid system
Among the 60 or so cannabinoids present in marijuana, only THC is psychoactive. However, cannabidiol, which is present in the hemp plant, have well-documented biological effects of potential therapeutic interest, such as antianxiety, anticonvulsive, antinausea, anti-inflammatory and antitumor properties. Cannabidiol does not significantly interact with CB1 or CB2 receptors, and its actions have been attributed to inhibition of anandamide degradation or its antioxidant properties, or an interaction with as yet unidentified cannabinoid receptors.
The emerging role of the endocannabinoid system in a variety of Central Nervous System disorders should not come as a surprise given the very high level of expression of endocannabinoid receptors in the brain. The particularly high density of endocannibinoid receptors in the cortex, cerebellum, hippocampus, and basal ganglia had drawn early attention to diseases affecting movement, mood and anxiety disorders, and conditions related to altered brain reward mechanisms, as well as processes of memory and learning.
Read the National Institutes of Health article here.


FDA Disclaimer:
The statements and products shown on this website have not been evaluated by the US Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Those seeking treatment for a specific disease should consult a qualified physician. This is not a medical site and is not intended to offer medical advice. Alpha Neurogenics, Inc. urges you to consult your health care provider for proper diagnosis. You should consult your health care provider prior to taking any dietary supplement. Alpha Neurogenics Inc. products should be taken as part of a healthy lifestyle. You must be at least 18 years old to visit our website and make product purchases.


Copyright © 2018 - 2020 All rights reserved. Alpha NeurogenicsTM, Alpha ICETM, Alpha BSCTM and Alpha FSCTM are the trademarks of
Pinnacle Brands, Inc. 8400 E Prentice Ave, Ste 1500, Greenwood Village CO 80111


TERMS OF USE  |  USA PRIVACY  |  EU USER CONSENT  |  CORPORATE INFORMATION  |  PRODUCT CERTIFICATION  |  AFFILIATE PROGRAM  |  WHOLESALE SALES
Shop Webstore
Rewards Club
Home Page
Create Account
Account Login
Ordering Info
Contact Us